|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/18 DelMar Pharmaceuticals, Inc. 10-Q 9/30/18 53:3.3M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 267K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 21K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
12: R1 Document and Entity Information HTML 42K
13: R2 Consolidated Condensed Interim Balance Sheets HTML 80K
(Unaudited)
14: R3 Consolidated Condensed Interim Balance Sheets HTML 36K
(Parenthetical) (Unaudited)
15: R4 Consolidated Condensed Interim Statements of Loss HTML 56K
and Comprehensive Loss (Unaudited)
16: R5 Consolidated Condensed Interim Statements of Cash HTML 68K
Flows (Unaudited)
17: R6 Going Concern, Nature of Operations, and Corporate HTML 36K
History
18: R7 Significant Accounting Policies HTML 51K
19: R8 Valent Technologies, LLC HTML 21K
20: R9 Derivative Liability HTML 34K
21: R10 Stockholders' Equity HTML 152K
22: R11 Financial Instruments HTML 41K
23: R12 Supplementary Statement of Cash Flows Information HTML 23K
24: R13 Subsequent Events HTML 21K
25: R14 Significant Accounting Policies (Policies) HTML 58K
26: R15 Derivative Liability (Tables) HTML 36K
27: R16 Stockholders' Equity (Tables) HTML 127K
28: R17 Financial Instruments (Tables) HTML 24K
29: R18 Supplementary Statement of Cash Flows Information HTML 21K
(Tables)
30: R19 Going Concern, Nature of Operations, and Corporate HTML 32K
History (Details)
31: R20 Significant Accounting Policies (Details) HTML 27K
32: R21 Valent Technologies, LLC (Details) HTML 37K
33: R22 Derivative Liability (Details) HTML 28K
34: R23 Derivative Liability (Details 1) HTML 29K
35: R24 Stockholders' Equity (Details) HTML 61K
36: R25 Stockholders' Equity (Details 1) HTML 32K
37: R26 Stockholders' Equity (Details 2) HTML 24K
38: R27 Stockholders' Equity (Details 3) HTML 91K
39: R28 Stockholders' Equity (Details 4) HTML 32K
40: R29 Stockholders' Equity (Details 5) HTML 24K
41: R30 Stockholders' Equity (Details 6) HTML 33K
42: R31 Stockholders' Equity (Details 7) HTML 25K
43: R32 Stockholders' Equity (Details 8) HTML 65K
44: R33 Stockholders' Equity (Details Textual) HTML 69K
45: R34 Stockholders' Equity (Details Textual 1) HTML 35K
46: R35 Stockholders' Equity (Details Textual 2) HTML 38K
47: R36 Stockholders' Equity (Details Textual 3) HTML 39K
48: R37 Financial Instruments (Details) HTML 24K
49: R38 Supplementary Statement of Cash Flows Information HTML 24K
(Details)
50: R39 Subsequent Events (Details) HTML 35K
52: XML IDEA XML File -- Filing Summary XML 90K
51: EXCEL IDEA Workbook of Financial Reports XLSX 49K
6: EX-101.INS XBRL Instance -- dmpi-20180930 XML 937K
8: EX-101.CAL XBRL Calculations -- dmpi-20180930_cal XML 72K
9: EX-101.DEF XBRL Definitions -- dmpi-20180930_def XML 435K
10: EX-101.LAB XBRL Labels -- dmpi-20180930_lab XML 845K
11: EX-101.PRE XBRL Presentations -- dmpi-20180930_pre XML 595K
7: EX-101.SCH XBRL Schema -- dmpi-20180930 XSD 140K
53: ZIP XBRL Zipped Folder -- 0001213900-18-015493-xbrl Zip 90K
Exhibit 31.2
Certifications
I, Scott Praill, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of DelMar Pharmaceuticals, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 13, 2018
|
/s/ Scott Praill |
|
| Scott Praill | |
|
Chief Financial Officer
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/13/18 | 4 | ||
| For Period end: | 9/30/18 | |||
| List all Filings | ||||